26 August 2022
RR Mechatronics (RRM) has achieved significantly higher turnover in the first half of 2022 compared to the first half of 2021. However, due to ongoing supply chain problems, it was not possible to deliver all our instruments on the initially confirmed date. The order book is still very high by RRM standards. This is mainly driven by the large first order for the RPI launched in December 2021. This order runs until April 2023. The turnover from the RPI line is on budget.
Sales from the Starrsed line of settling instruments are slightly behind budget due to the aforementioned supply chain problems. Looking at the orders already placed by customers for the 2nd half of 2022, a higher than budgeted turnover is expected with the Starrsed line.
The Lorrca line still suffers from delayed design and implementation of clinical trials. The order intake was almost on budget in the first half of 2022, but there was a delay in delivery, which is expected to be made up in the third quarter of 2022. The expectations for the whole of 2022 are that the budgeted turnover will be achieved. The aforementioned and important sickle cell drug trial in Nigeria will start next September.
Despite the supply chain problems, we have been able to continue to provide the users of our instruments with reagents, parts and support. Our stocks have been adjusted to high(er) levels for this purpose.
As mentioned during the meeting of bondholders on July 14, the introduction of the new Starrsed line has been delayed. To absorb the additional expenses resulting from this delay in the introduction of the new Starrsed line, RRM shareholders have strengthened their equity by €2022 million in the first half of 3. We expect to be able to announce the introduction schedule during the third quarter of 2022.
Jan Buis
CEO
